5 Results for "

IIA site

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "IIA site" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-N10686
CAS No.: 61077-78-9
Tanshinone IIA anhydride, present in root extracts of Salvia miltiorrhiza, acts as an inhibitor of human carboxylesterase (CE). Tanshinone IIA anhydride has a Ki value of 1.9 nM against hCE1 and a Ki value of 1.4 nM against hiCE. Tanshinone IIA anhydride forms a stable covalent complex with serine Ser221 at the active site of hCE1, blocking the catalytic cycle of carboxylesterase, and the activity of the inactivated enzyme cannot recover spontaneously. Tanshinone IIA anhydride is applicable in metabolism-related studies .
loading...
    loading...
Cat. No.: HY-P5107
CAS No.: 121052-30-0
Synonyms: LMWP; TDSP5
Target:  

VEGFR

Research Areas:  

Cancer

Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities, and also neutralizes anti-Xa activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds .
loading...
    loading...
Cat. No.: HY-P5107A
Synonyms: LMWP acetate; TDSP5 acetate
Target:  

VEGFR

Research Areas:  

Cancer

Low molecular weight protamine acetate (LMWP acetate;TDSP5 acetate) is a truncated arginine-rich protamine peptide, which also acts as an antidote for heparin/low molecular weight heparin and a cell-penetrating delivery vector. Low molecular weight protamine acetate neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities. Low molecular weight protamine acetate translocates across mammalian cell membranes, delivers conjugated impermeable molecules through tumor tissues, enhances the skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine acetate retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine acetate can be used in studies related to colon cancer, skin wounds and diabetic skin wounds .
loading...
    loading...
Cat. No.: HY-NP229
DNP-BSA is a multivalent antigen and protein-binding reagent. DNP-BSA binds to subdomain IIA (Site I) of bovine serum albumin via predominantly hydrophobic forces, with spontaneous complex formation via combined dynamic and static quenching. DNP-BSA induces cross-linking of IgE-bound FceRI, triggering tyrosine phosphorylation of FceRI β and γ subunits. DNP-BSA binds to anti-DNP IgE via its DNP groups, forming cross-links between IgE-FceRI complexes, with most DNP groups initially unavailable but transiently exposed for binding. DNP-BSA induces FITC fluorescence quenching in FITC-labeled anti-DNP IgE, proportional to occupied IgE Fab binding sites. DNP-BSA can be used for the research of allergy, inflammation, and contact sensitivity (allergic contact dermatitis) .
loading...
    loading...
Cat. No.: HY-187618
CAS No.: 1508276-29-6
Target:  

TRP Channel

Research Areas:  

Metabolic Disease

GRC-17536 is a TRPA1 antagonist with selective inhibition of TRPA1-mediated calcium influx .GRC-17536 binds to TRPA1 binding site 2 to inhibit channel activity .GRC-17536 reduces irritant-induced cough responses and citric acid-induced cough responses .GRC-17536 exhibits antitussive activity .GRC-17536 has poor pharmacokinetic and bioavailability properties, leading to discontinued development after a Phase IIa study .GRC-17536 can be used for the research of painful diabetic polyneuropathy, peripheral diabetic neuropathy, asthma, and chronic cough .
loading...
    loading...